The authors also confirmed the potential role of CCNE1 as a predictive biomarker in an independent validation cohort of breast cancer patients from the preoperative palbociclib study, where high CCNE1 levels were associated with a decreased antiproliferative effect with palbociclib. The gene discussed is CCNE1; the disease is breast cancer.